Abstract
Hepatitis C virus (HCV) is a major human pathogen, infecting an estimated 170 million persons worldwide, roughly five times the number infected by HIV type 1. A substantial fraction of these HCV infected individuals develop serious progressive liver disease, including cirrhosis and hepatocellular carcinoma. The current treatment regimen suffers from various side effects. These limitations encourage the search of more effective HCV inhibitors. To achieve this objective a quantitative structure-activity relationship (QSAR) study has been made on three different series of anti-HCV agents that are comprised of pyrrolo[2,3-d]pyrimidine nucleoside derivatives, benzimidazole-coumarin conjugates, and ribonucleoside analogues, respectively. The QSAR analysis reveals that anti-HCV potencies of these series of compounds are controlled by a topological parameter (Kiers first order valence molecular connectivity index 1χv), lipophilicity, and the molar refractivity of the compounds, respectively. Based on these results, the mechanisms of drug-receptor interactions of these compounds are discussed, which may be of great help to design and develop more anti-HCV agents.
Keywords: Anti-hepatitis C virus (HCV) agents, Hepatitis C virus inhibitors, QSAR study, Pyrrolo[2,3-d]pyrimidine nucleoside derivatives, Benzimidazole-coumarin conjugates, Ribonucleoside analogues
Letters in Drug Design & Discovery
Title: A QSAR Study on Some Series of Anti-Hepatitis C Virus (HCV) Agents
Volume: 7 Issue: 2
Author(s): Vaishali M. Patil, S. P. Gupta and S. Samanta
Affiliation:
Keywords: Anti-hepatitis C virus (HCV) agents, Hepatitis C virus inhibitors, QSAR study, Pyrrolo[2,3-d]pyrimidine nucleoside derivatives, Benzimidazole-coumarin conjugates, Ribonucleoside analogues
Abstract: Hepatitis C virus (HCV) is a major human pathogen, infecting an estimated 170 million persons worldwide, roughly five times the number infected by HIV type 1. A substantial fraction of these HCV infected individuals develop serious progressive liver disease, including cirrhosis and hepatocellular carcinoma. The current treatment regimen suffers from various side effects. These limitations encourage the search of more effective HCV inhibitors. To achieve this objective a quantitative structure-activity relationship (QSAR) study has been made on three different series of anti-HCV agents that are comprised of pyrrolo[2,3-d]pyrimidine nucleoside derivatives, benzimidazole-coumarin conjugates, and ribonucleoside analogues, respectively. The QSAR analysis reveals that anti-HCV potencies of these series of compounds are controlled by a topological parameter (Kiers first order valence molecular connectivity index 1χv), lipophilicity, and the molar refractivity of the compounds, respectively. Based on these results, the mechanisms of drug-receptor interactions of these compounds are discussed, which may be of great help to design and develop more anti-HCV agents.
Export Options
About this article
Cite this article as:
Patil M. Vaishali, Gupta P. S. and Samanta S., A QSAR Study on Some Series of Anti-Hepatitis C Virus (HCV) Agents, Letters in Drug Design & Discovery 2010; 7 (2) . https://dx.doi.org/10.2174/157018010790225877
DOI https://dx.doi.org/10.2174/157018010790225877 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacogenetics in Methadone Therapy
Current Pharmacogenomics and Personalized Medicine From TGF-β to Cancer Therapy
Current Drug Targets The Modification of Serum Lipids after Acute Coronary Syndrome and Importance in Clinical Practice
Current Cardiology Reviews Pharmacological Intervention in Type 2 Diabetes Mellitus – A Pathophysiologically Reasoned Approach?
Current Diabetes Reviews Properties of the Mesenchymal Endometriotic Stem Cell in the Context of the Immune System and Analysis of its Role in Endometriosis
Recent Patents on Regenerative Medicine The Therapeutic Potential of Novel Kappa Opioid Receptor-based Treatments
Current Medicinal Chemistry Phytotherapeutic and Natural Compound Applications for Age-Related, Inflammatory and Serious Eye Ailments
Current Molecular Pharmacology Reporting and Interpretation of the CYP2C19 Genotyping Test for Clopidogrel Dosing
Current Pharmacogenomics and Personalized Medicine Patents in Cancer Stem Cells
Recent Patents on Biomarkers TNFα Modulation of Visceral and Spinal Sensory Processing
Current Pharmaceutical Design Anti-Inflammatory Role of Thyroid Hormones on Rat Air Pouch Model of Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) Metformin one in a Million Efficient Medicines for Rheumatoid Arthritis Complications: Inflammation, Osteoblastogenesis, Cardiovascular Disease, Malignancies
Current Rheumatology Reviews Gene Therapy in Cardiovascular Diseases
Current Gene Therapy Evaluation of Skin Permeability of Resveratrol Loaded Liposomes and Nanostructured Lipid Carriers using a Skin Mimic Artificial Membrane (skin-PAMPA)
Drug Delivery Letters Repurposed Drugs for the Treatment of Schizophrenia and Bipolar Disorders
Current Topics in Medicinal Chemistry The Innovations in Pulmonary Hypertension Pathophysiology and Treatment: What are our Options!
Current Respiratory Medicine Reviews Gossypium herbaceam L. Extracts Ameliorate Disequilibrium of IL- 1RA/IL-1β Ratio to Attenuate Inflammatory Process induced by Amyloid β in Rats
Current Alzheimer Research The Brainstem Tau Cytoskeletal Pathology of Alzheimer’s Disease: A Brief Historical Overview and Description of its Anatomical Distribution Pattern, Evolutional Features, Pathogenetic and Clinical Relevance
Current Alzheimer Research Swimming Impacts on Pancreatic Inflammatory Cytokines, miR-146a and NF-кB Expression Levels in Type-2 Diabetic Rats
Current Diabetes Reviews Signal Transduction Therapy of Diabetic Vascular Complication
Current Signal Transduction Therapy